BD, Franklin Lakes, NJ, has announced the receipt of CE mark certification for its FacsDuet automated flow cytometry sample preparation system. The fully automated sample preparation unit enables clinical laboratories to improve their efficiency by reducing errors and limiting the manual user interactions required to run assays on the company’s FacsLyric clinical flow cytometer.
The FacsDuet system builds new capabilities into BD’s portfolio of clinical flow cytometry solutions. Collectively, the company’s solutions may help clinical laboratories improve the accuracy and repeatability of their assays by minimizing manual steps that can introduce errors.
“The BD FacsDuet system enables us to increase our laboratory’s efficiency and throughput, replacing manual processes with automated ones that are traceable and that can be automatically transferred and recorded in our laboratory information system, providing a complete audit trail,” says David Bloxham, principal biomedical scientist in the hematooncology diagnostic service at Cambridge University Hospital NHS Trust.
Physical integration of the FacsDuet system and the FacsLyric clinical flow cytometer allows technicians to load samples and reagents onto the FacsDuet system and to receive data from the FacsLyric clinical flow cytometer once the samples are fully processed. Data integration using BD’s FacsLink middleware solution provides bidirectional communication between the components and connectivity with laboratory information systems.
“Introduction of the BD FacsDuet system is the natural continuation of our 40-year history of making reliable flow cytometry solutions that are more robust and easier to use,” says John Ledek, worldwide president for biosciences at BD. “Automation solutions for flow cytometry can go a long way towards improving accuracy and standardization from instrument to instrument, providing the consistent results that clinicians depend on to inform patient care.”
The FacsDuet automated flow cytometry sample preparation system is available for in vitro diagnostic applications in Europe, and is expected to be available in other geographies as soon as regulatory milestones are secured.
For further information, visit BD Biosciences.